MEDIA
News
Hemostatic Gel Immediately Stops Multiple Types of Bleeds Without Need to Apply Pressure
Cresilon is using recycled algae, meaning algae or kelp that has washed up onto the shoreline. The vendors they work with are highly sustainable as they are not damaging kelp forests but salvaging material that has already washed up on beaches.
Interview: 17-year-old invents life-saving gel technology
When he was 17 years old, Joe Landolina created a revolutionary gel. Now, he is 29 years old and co-founder and CEO of Cresilon, his homegrown Brooklyn-based biotech company that recently submitted the gel for FDA 510(k) clearance for human use and raised $38.5 million in Series A3 financing last year. DDW’s Megan Thomas caught up with Landolina about his success story.
Stopping Bleeding with Algal-Based Polymers
“Catastrophic bleeding is a cause of death after a wide variety of wounds in humans and other animals. This week’s podcast speaks with Joe Landolina from Cresilon, describing natural polymers that immediately cease bleeding, along with their military, medical and veterinary applications.”
How This Plant-Based Gel Can Treat Wounds
Brooklyn Native Creates Gel Bandage
“There are over three million bleeds every single year in animal health and many more bleeds on the human side that we’re hoping to eventually be able to target,” Landolina said.
Cresilon’s gel used for animals to stop bleeding in seconds
Nov. 08, 2021 – 3:54 – Cresilon CEO Joe Landolina discusses life-saving innovation on Fox Business.
Brooklyn Heights native's company Cresilon creates gel to stop bleeding
Not many college freshmen start a business as soon as they get to school. However, Brooklyn Heights’ Joe Landolina had other plans in mind when starting his company Cresilon Inc.
Press Releases
Cresilon and Walter Reed Army Institute of Research Sign Cooperative R&D Agreement for Treatment of Traumatic Brain Injuries
“Cresilon is extremely proud and honored to be supporting the DoD and WRAIR in this critically important work,” said Joe Landolina, CEO of Cresilon. “This collaboration is a testament to the potential of our technology, and we are truly hopeful that it can make a difference in the treatment of TBI and in the precious lives of our soldiers.”
Cresilon Announces FDA 510(k) Submission For Human Use Hemostatic Gel Technology
“This FDA submission marks an important milestone for Cresilon in our commitment to significantly improve the standard of care in wound treatment,” said Joe Landolina, CEO of Cresilon.
Cresilon Closes $38.5 Million Series A-3 Financing
Subscribe to our Newsletter
Stay in touch with us to get Cresilon’s news, investment opportunities, and product releases.
Address
122 18th St, Brooklyn, NY 11215 USA
Call Us
(347) 435-2226
Email Us
info@cresilon.com